B7-33 wird in der Forschung im Bereich Geweberegeneration und -reparatur untersucht, u. a. in Zell- und Tiermodellen. Wirkt als funktionsselektiver Partialagonist am RXFP1-Rezeptor: Es aktiviert bevorzugt den pERK1/2-MMP2-Signalweg anstelle des klassischen cAMP-Signalwegs des vollständigen Relaxins, wodurch antifibrotische Effekte erzielt werden.
Used in cardiovascular and pulmonary research to study organ fibrosis and tissue remodeling, and as a tool to investigate receptor-selective GPCR signaling.
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Studies on regenerative peptides are mostly derived from cell culture and animal models; comprehensive clinical data is typically still limited.
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
We reply personally – via email or Telegram.